PlantForm appoints Doug Cossar Vice-President, Research
Cossar brings 30 years experience in biotech research to the role
GUELPH, Ont.—August 10, 2016
PlantForm Corporation is pleased to announce the appointment of Dr. Doug Cossar as Vice-President, Research, effective immediately.
Cossar will lead PlantForm's research team, overseeing the development of the company's intellectual property portfolio, continued improvements to the company's vivoXPRESS® biopharmaceutical production platform and evaluation of potential new drug candidates.
"Doug has supported PlantForm as a member of our Scientific Advisory Board since the company was founded in 2008, and we are pleased to welcome him in this new role," said Dr. Don Stewart, PlantForm President and CEO.
"His deep experience in biotech research is a valuable asset as we continue to advance the capabilities of our plant-based manufacturing platform to deliver a wide range of innovator and biosimilar drugs."
“I am extremely pleased to join an innovative and forward-thinking company developing products that will contribute greatly to human health and well-being,” said Cossar.
Cossar has 30 years of experience in the biotech industry, most recently as research manager, biotechnology, at Croda Europe Ltd. His career path also includes serving as principal investigator, biotechnology, for the Structural Genomics Consortium, and senior positions at Canadian biotech company Cangene and the Public Health Laboratory Service in the U.K.
He has a PhD in Microbiology from Heriot-Watt University, Edinburgh. His expertise spans protein expression and analysis, GMP manufacturing for biopharmaceuticals, process validation, natural product manufacturing, as well as research experience in microalgae and fungal biochemistry/physiology, protein structural biology and synthentic biology.
About PlantForm Corporation (www.plantformcorp.com) PlantForm is a Canadian biotech company with a low-cost proprietary manufacturing platform for a wide range of plant-made pharmaceuticals, including monoclonal antibodies, therapeutic proteins and vaccines for the treatment of cancer, HIV/AIDS, Ebola and other life-threatening conditions. The company’s vivoXPRESS® technology uses genetically engineered tobacco plants to produce biopharmaceuticals at a significantly lower cost of goods compared to industry standard fermentation systems. Learn more.
For more information, please contact:
Join us online!
Get regular updates on our activities and industry news by following PlantForm on Twitter, LinkedIn and Facebook: